Crispr Therapeutics Ag Net Income per Employee (CRSP), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Crispr Therapeutics Ag  (NASDAQ: CRSP)
 

Crispr Therapeutics Ag Net Income per Employee

CRSP's Quarterly Results, Trends, Rankings, Statistics
Crispr Therapeutics Ag recorded a cumulative net loss of $-569 million during 12 month ending in the first quarter 2026.
The Healthcare sector has seen employees of 133 other companies achieving higher income per employee. While income per employee total ranking has improved so far to 4091, from total ranking in previous quarter at 4861.


What is Income per Employee Ratio?






CRSP Net Income per Employee (Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
(Mar 31 2025)
I. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -2,828,527 -2,893,527 -2,429,338 -2,327,353 -1,918,692
CRSP's Total Ranking # 4091 # 4861 # 4250 # 4301 # 4283
Seq. Net Income Change - - - - -


CRSP Net Income per Employee Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 134
Healthcare Sector # 836
Overall Market # 4091

Net Income per Employee Statistics
High Average Low
$ 2,221,811 $ -959,807 $ -3,387,303
(Jun 30 2021)   (Sep 30 2022)







Companies with similar Income per Employee for 12 month ending Mar 31 2026, within Healthcare Sector Income per Employee Income 12 month ending Mar 31 2026Number of Employees Mar 31 2026


Date modified: 2026-08-29T17:37:15+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.